Efficacy of High-Dose Methylprednisolone in Inducing Remission in Pediatric Acute Severe Ulcerative Colitis:...

Area of Science:

• Pediatric Gastroenterology
• Inflammatory Bowel Disease Research
• Clinical Pharmacology

Background:

• Ulcerative colitis (UC) incidence is rising, particularly in pediatric populations.
• Current UC treatment focuses on inducing and maintaining remission.
• Standard therapies include 5-aminosalicylic acid, oral steroids, and intravenous methylprednisolone for severe cases.

Purpose of the Study:

• To evaluate the efficacy of high-dose intravenous methylprednisolone pulses in inducing remission in pediatric patients with moderate to severe ulcerative colitis.
• To assess the safety and effectiveness of this treatment regimen.

Main Methods:

• Retrospective case series of pediatric patients (<18 years) hospitalized for UC flares between 2018-2021.
• Patients received high-dose intravenous methylprednisolone (30 mg/kg/day, max 1 g for 3-5 days).
• Treatment response was measured using the Pediatric Ulcerative Colitis Activity Index (PUCAI), with remission defined as a ≥20-point reduction or a score <10.

Main Results:

• The study included 15 pediatric UC patients, most with severe disease (12/15).
• A significant clinical response was observed in 9/15 patients (60%), with a mean PUCAI decrease of 39.4 points.
• Median time to clinical remission was 4 days, with no adverse effects reported during treatment.

Conclusions:

• High-dose intravenous methylprednisolone pulses demonstrate potential as a remission-inducing therapy for pediatric ulcerative colitis.
• The findings suggest this approach may be a viable alternative for moderate to severe cases.
• Further prospective studies are recommended due to the study's small sample size and retrospective nature.